Description du projet
Un pancréas artificiel automatisé pour le traitement du diabète de type 1
Le diabète de type 1 (DT1) est lié à un manque de cellules productrices d’insuline dans le pancréas et est généralement diagnostiqué chez les enfants et les jeunes adultes. Tout au long de leur vie, les patients atteints de DT1 ont besoin d’insuline exogène. Le projet FORGETDIABETES, financé par l’UE, introduit une toute nouvelle approche du traitement du DT1 avec le développement d’un pancréas bionique invisible (BIP, pour bionic invisible pancreas) immuno-optimisé, entièrement implantable et automatisé. Le BIP favorisera l’apport intrapéritonéal d’insuline pour permettre un contrôle optimal de la glycémie. L’équipe du projet comprend les meilleurs experts en micro–nano mécatronique, en biomatériaux, en endocrinologie, en chirurgie et en sciences comportementales. Le BIP durable reposera sur un système de détection physiologique du glucose et de délivrance de l’insuline contrôlé par des algorithmes adaptatifs personnalisés dotés de capacités avancées d’autodiagnostic.
Objectif
FORGETDIABETES introduces a radically new approach to Type 1 Diabetes (T1D) treatment, by developing an immuno-optimized, fully-implantable, fully-automated, Bionic Invisible Pancreas (BIP). BIP targets physiological intraperitoneal hormone delivery, enabling an optimal glycemic control. T1D patient number is rising, projected at 63-94 million in 2045. T1D patients require exogenous insulin, resulting in an exorbitant number of actions: 100.000-500.000 in one patient’s life. BIP will free T1D subjects from therapeutic actions and from related psychological burden. BIP will become a life-condition (like wearing glasses), allowing T1D patients to live just as everybody else. An interdisciplinary team with top experts in micro-nano mechatronics, control engineering, biomaterials, endocrinology, surgery and behavioural sciences has been assembled to develop what was regarded as impossible for decades: a long-lasting system relying on a physiological glucose sensing and hormone delivery, orchestrated by personalized adaptive algorithms with advanced self-diagnostic capabilities. Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of painful and awkward daily measurement and treatment actions.
Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. In this project, the key technologies enabling BIP will be developed. Furthermore, extensive in vivo preclinical experiments along with massive in silico testing will establish the proof-of-principle, paving the way to the ambitious first-in-human inpatient trial of BIP. This paradigm will revolutionize diabetes treatment and stimulate an innovation ecosystem including research bodies, SMEs, patient organizations, diabetes societies and clinicians. By investing in efforts like FORGETDIABETES, Europe will stand at the forefront of technological innovations for T1D treatment.
Champ scientifique
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesclinical medicineendocrinologydiabetes
- engineering and technologymechanical engineeringmechatronics
- engineering and technologyindustrial biotechnologybiomaterials
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringcontrol engineering
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
35122 Padova
Italie